Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Docket		Date Filed	2016-12-07
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	9,439,900
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-07				External link to document
2016-12-06	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,439,900 B2. (jcs) (Entered:…2016 10 January 2019 1:16-cv-01139 830 Patent Defendant District Court, D. Delaware	External link to document

Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-01139: Litigation Summary and Patent Analysis

Last updated: September 29, 2026

Orexo AB’s Hatch-Waxman action against Actavis Elizabeth LLC challenged Actavis’s abbreviated new drug application for a generic version of Zubsolv, Orexo’s buprenorphine/naloxone sublingual tablet for opioid dependence. The case centered on U.S. Patent No. 8,940,330. The District of Delaware initially found the asserted claims obvious, but the Federal Circuit reversed that ruling in 2018. The appellate decision strengthened Orexo’s position and required further proceedings consistent with the Federal Circuit’s finding that the prior art did not establish obviousness.

What drug and patent were at issue in Orexo v. Actavis?

The case concerned Zubsolv, a sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride. Orexo markets Zubsolv for maintenance treatment of opioid dependence in conjunction with a complete treatment plan that includes counseling and psychosocial support.

Actavis submitted an ANDA seeking approval to market a generic buprenorphine/naloxone sublingual product. Orexo sued under the Hatch-Waxman Act after receiving Actavis’s Paragraph IV certification challenging the relevant patent.

Item	Case detail
Plaintiff	Orexo AB
Defendant	Actavis Elizabeth LLC
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-01139
District judge	Richard G. Andrews
Product	Zubsolv buprenorphine/naloxone sublingual tablets
Generic pathway	ANDA and Paragraph IV certification
Principal patent	U.S. Patent No. 8,940,330
Federal Circuit citation	Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018)

The patent covered pharmaceutical compositions containing buprenorphine and naloxone formulated for sublingual administration. The claimed formulation was directed to a combination that provided the relevant drug-delivery and dissolution characteristics of Zubsolv.

What patent protected Zubsolv in the Actavis litigation?

The central patent was U.S. Patent No. 8,940,330, titled “Pharmaceutical composition.” The patent issued on January 27, 2015. Orexo asserted the patent against Actavis’s ANDA product.

The dispute focused on whether the claimed buprenorphine/naloxone composition would have been obvious in view of earlier buprenorphine and naloxone products and formulation references. The Federal Circuit’s opinion addressed the patentability of the claimed formulation, rather than merely the presence of the active ingredients.

The asserted patent’s commercial relevance came from its coverage of a sublingual dosage form combining:

• buprenorphine;
• naloxone;
• an excipient system; and
• formulation characteristics relevant to sublingual administration and dissolution.

The case illustrates the distinction between patenting the active ingredients and patenting a particular delivery system. Buprenorphine and naloxone were known compounds. Orexo’s litigation position depended on the non-obviousness of the specific formulation and its performance characteristics.

Patent term and Orange Book relevance

Patent expiration dates must be confirmed against the USPTO patent-term calculation and the FDA’s current Orange Book listing. The ’330 patent was issued in 2015 and had a statutory term extending into the early 2030s based on its priority and filing history, subject to any applicable patent-term adjustment or other term calculation.

The litigation record and Federal Circuit opinion establish that the ’330 patent was the principal patent adjudicated in this action. They do not, by themselves, establish the complete and current Orange Book listing for every Zubsolv strength or later-issued Orexo patent.

When did Orexo sue Actavis over generic Zubsolv?

Orexo filed the action in 2016 after Actavis notified Orexo of its Paragraph IV certification. Under the Hatch-Waxman framework, the filing of the patent infringement action triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions or an earlier court resolution.

The case was filed as:

Procedural event	Date or period
Complaint filed	2016
District court action	1:16-cv-01139
Trial-level validity ruling	Before Federal Circuit appeal
Federal Circuit decision	September 2018
Federal Circuit disposition	Reversal and remand

The filing date and case number identify the action, but the ultimate commercial launch date for Actavis’s ANDA product cannot be inferred solely from the complaint or the appellate opinion.

What did the District of Delaware decide?

The District of Delaware granted summary judgment that the asserted claims of the ’330 patent were invalid as obvious. The court concluded that the prior art provided a sufficient basis for a skilled artisan to arrive at the claimed formulation.

The district court’s reasoning treated the formulation as an arrangement of known ingredients and formulation choices. The analysis focused on whether the prior art supplied a motivation to combine the relevant components and whether a skilled artisan would have had a reasonable expectation of success.

That ruling eliminated the patent barrier at the trial level. Orexo appealed to the Federal Circuit.

How did the Federal Circuit rule in 2018?

The Federal Circuit reversed the obviousness ruling. In Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018), the court held that the district court’s analysis did not adequately establish that the claimed formulation would have been obvious.

The Federal Circuit emphasized several points:

1. The prior art did not provide the required motivation to combine the relevant formulation components in the claimed manner.
2. The record did not establish a reasonable expectation of success.
3. The district court relied too heavily on hindsight and on the known desirability of the claimed result.
4. The formulation’s properties and the prior art’s teachings had to be evaluated in the context of the claimed combination.

The appellate court rejected the proposition that the existence of known buprenorphine and naloxone products made the claimed formulation predictable. A formulation patent can remain non-obvious even when each ingredient is individually known.

The decision did not create a categorical rule that pharmaceutical formulations are non-obvious. It applied the established obviousness framework to the specific evidence concerning Zubsolv’s formulation, prior art, motivation to combine and expectation of success.

Why was the formulation patent considered stronger than an active-ingredient patent?

The strength of Orexo’s position came from the structure of the claim. The patent did not attempt to exclude all use of buprenorphine or naloxone. It claimed a particular pharmaceutical composition designed for sublingual delivery.

This distinction mattered because:

• buprenorphine was an established opioid partial agonist;
• naloxone was an established opioid antagonist;
• the combination was known in opioid-dependence treatment;
• the disputed issue was whether the claimed excipient and dosage-form combination was an obvious formulation choice.

The Federal Circuit’s reasoning treated formulation performance as relevant to the obviousness inquiry. The claimed product was not evaluated only by listing its ingredients. The interaction among the ingredients, excipients and delivery characteristics affected the patentability analysis.

What was the Paragraph IV challenge?

Actavis’s ANDA included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable or not infringed. A Paragraph IV certification is an explicit challenge to a listed patent and permits the patent holder to bring an infringement action before generic approval.

Orexo’s lawsuit alleged that Actavis’s proposed ANDA product would infringe the ’330 patent. The filing of the lawsuit triggered the Hatch-Waxman litigation process, including the statutory approval stay.

The Federal Circuit decision addressed patent validity. It did not establish a broad rule that all generic Zubsolv products would infringe every Orexo patent or that every Actavis product would be blocked until the full patent term.

What was the main legal issue: obviousness or infringement?

The principal appellate issue was obviousness. The Federal Circuit’s opinion focused on whether the asserted claims were invalid under 35 U.S.C. § 103.

The case was not primarily resolved through a finding that the active ingredient combination itself was novel. The central question was whether the specific formulation claimed by Orexo would have been obvious to a person of ordinary skill in the art.

The Federal Circuit’s reversal meant that the district court’s invalidity judgment could not stand. The appellate court remanded for further proceedings.

What did the Federal Circuit decision mean for generic entry?

The ruling removed the district court’s immediate invalidity judgment and restored the patent as a potentially enforceable barrier. It materially increased the litigation risk for Actavis and reduced the likelihood that Actavis could rely on the trial-level invalidity ruling to obtain approval and launch without further proceedings.

The decision did not itself establish:

• a final generic launch date;
• a permanent injunction;
• a settlement date;
• an agreed license;
• or the commercial terms of any later resolution.

Those matters depend on the post-remand docket and any confidential or public settlement agreement.

From a market-access perspective, the ruling gave Orexo leverage in any subsequent settlement negotiations. A successful validity appeal generally improves the brand company’s position on launch timing, damages exposure and potential licensing terms.

Did Orexo and Actavis enter a settlement agreement?

The public appellate decision does not disclose a settlement agreement. A complete assessment of settlement terms requires the post-remand docket, any consent judgment and applicable FDA approval records.

The case record available through the cited appellate decision establishes the following:

• Actavis challenged Orexo’s patent through Paragraph IV certification.
• Orexo sued in the District of Delaware.
• The district court found the patent obvious.
• The Federal Circuit reversed that finding.
• The case was remanded.

The appellate opinion does not state that Actavis received a license, agreed to a specific launch date or entered a public reverse-payment settlement.

What is the litigation status of Orexo v. Actavis?

The Federal Circuit’s September 2018 decision reversed the trial court’s obviousness judgment and remanded the matter. The appellate opinion is the controlling public decision for the principal legal issue.

The practical status should be described as follows:

Issue	Status
District court invalidity ruling	Reversed
’330 patent obviousness finding	Rejected by Federal Circuit
Federal Circuit appeal	Decided in Orexo’s favor on obviousness
Case disposition	Remanded
Publicly established launch date	Not established by the appellate opinion
Publicly established settlement terms	Not established by the appellate opinion
Patent barrier after appeal	Reinstated as a material litigation barrier, subject to remand proceedings and later events

A docket-level review is required to state the final post-remand judgment, any injunction, or any later settlement with precision. The Federal Circuit opinion alone does not provide those details.

How strong was Orexo’s patent estate after the Federal Circuit ruling?

The ’330 patent became materially stronger after the Federal Circuit decision because the appellate court rejected the trial court’s obviousness analysis. The decision also provided useful prosecution and litigation guidance for formulation patents involving known active ingredients.

The patent’s strength can be assessed across four dimensions:

Dimension	Assessment
Active ingredient novelty	Limited, because buprenorphine and naloxone were known
Formulation novelty	More significant, because the claims focused on a specific sublingual composition
Obviousness risk	Reduced after the Federal Circuit reversal
Design-around risk	Remained relevant because a competitor could alter excipients, ratios, dissolution properties or dosage-form structure

The ruling did not eliminate all validity risks. A patent can survive one obviousness challenge and remain exposed to other prior-art arguments, written-description challenges, enablement issues, infringement defenses or later petitions.

What generic launch scenarios did the case create?

The principal launch scenarios were:

Actavis loses on remand or settles without an immediate license

Orexo could preserve the patent barrier for the relevant patent term, subject to enforceability and any court-ordered relief.

Actavis obtains a license with a delayed launch

A settlement could permit entry before patent expiration on an agreed date. The appellate opinion does not disclose such an agreement.

Actavis prevails on another ground after remand

A successful non-obviousness appeal did not prevent Actavis from pursuing other defenses, including non-infringement or invalidity on another statutory ground.

Actavis designs around the patent

A generic applicant could seek approval for a formulation that avoids the asserted claims. The commercial feasibility of that route would depend on the claim language, FDA requirements and the substitutability of the resulting product.

What were the commercial implications for Zubsolv?

The case protected Orexo’s ability to defend Zubsolv against at least one major ANDA challenge. Zubsolv competes in the medication-assisted treatment market with other buprenorphine/naloxone products, including Suboxone tablets and films, generic buprenorphine/naloxone products and other opioid-use-disorder therapies.

The litigation mattered because Zubsolv’s value was tied to:

• its sublingual tablet dosage form;
• its buprenorphine/naloxone formulation;
• its product differentiation from film products;
• its FDA-approved opioid-dependence indication;
• and the timing of generic competition.

A successful patent challenge could have accelerated generic substitution and reduced price protection. The Federal Circuit reversal delayed that risk or increased the cost of an immediate generic launch.

The case did not establish that Orexo had exclusive rights over all buprenorphine/naloxone products. Its commercial protection depended on the scope and remaining term of the asserted patent and any other applicable patents or regulatory exclusivities.

How does this case compare with biosimilar litigation?

This was a small-molecule Hatch-Waxman case, not a biologics or biosimilar case. The relevant framework was an ANDA Paragraph IV challenge under the Drug Price Competition and Patent Term Restoration Act.

Biosimilar litigation under the Biologics Price Competition and Innovation Act involves different regulatory submissions, patent-exchange procedures and exclusivity concepts. Biosimilar risk is therefore not directly applicable to Zubsolv.

The relevant competitive threats were generic ANDA products and formulation design-arounds, not biosimilars.

Key Takeaways

• Orexo sued Actavis in the District of Delaware over an ANDA for generic Zubsolv.
• The principal patent was U.S. Patent No. 8,940,330.
• The district court initially found the asserted patent claims obvious.
• The Federal Circuit reversed that ruling in 2018.
• The appellate decision treated the claimed formulation as more than a predictable combination of known ingredients.
• The ruling strengthened Orexo’s negotiating and enforcement position.
• The appellate opinion does not disclose a final launch date, settlement, license or post-remand commercial agreement.
• The case is a leading Federal Circuit decision on obviousness of pharmaceutical formulations containing known active ingredients.

FAQs About Orexo AB v. Actavis Elizabeth LLC

What product did Actavis seek to market?

Actavis sought approval for a generic buprenorphine/naloxone sublingual product corresponding to Orexo’s Zubsolv product.

What patent number was litigated?

The central patent was U.S. Patent No. 8,940,330.

Who won the Federal Circuit appeal?

Orexo prevailed on the principal obviousness issue. The Federal Circuit reversed the district court’s invalidity ruling and remanded the case.

Did the Federal Circuit hold that all generic buprenorphine/naloxone products infringe?

No. The decision addressed the validity of the asserted formulation claims. It did not establish infringement by every generic buprenorphine/naloxone product.

Is Zubsolv protected by biosimilar exclusivity?

No. Zubsolv is a small-molecule drug regulated through the NDA and ANDA framework. Biosimilar exclusivity does not apply.

References

1. Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,940,330: Pharmaceutical composition. USPTO.

4. U.S. District Court for the District of Delaware. (2016). Orexo AB v. Actavis Elizabeth LLC, No. 1:16-cv-01139. PACER docket record.

5. U.S. Food and Drug Administration. (2013). Zubsolv prescribing information. FDA.